Background The majority of prolactinomas respond to dopamine agonist therapy, but a
proportion are resistant, requiring other treatments including surgery and/or radiotherapy …

Prolactinomas are common tumors of the anterior pituitary gland. While conventional
therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are …

Abstract Pituitary tumors represent 10–15% of all intracranial tumors; of these, prolactinomas
account for 40–50% of cases. Prolactinomas usually respond well to dopamine agonists …

Interventions: The patient received the most frequently recommended regimen of
temozolomide treatment for 22 cycles. Outcomes: Temozolomide resulted in a remarkable …

Purpose Aggressive prolactinomas are defined as radiologically invasive tumors which
cannot be cured by surgery, and that have an unusually rapid rate of tumor growth despite …

BACKGROUND AND IMPORTANCE: The case presented here describes the clinical
evolution of a pituitary carcinoma from an atypical prolactinoma after temozolomide (TMZ) …

Administration of temozolomide to a 46-year-old man with an invasive aggressive prolactin
(PRL)–secreting pituitary neoplasm resulted in improvement of the clinical condition and …

Temozolomide (TMZ) has been shown as an effective treatment option in aggressive
pituitary adenomas and carcinomas. This review analyses the published case series and …

Eur J Clin Invest 2011; 41 (10): 1133–1148 Abstract Background Aggressive pituitary
tumours are associated with substantial morbidity and mortality. Treatment options are often …

Purpose Refractory prolactinomas resistant to dopamine agonists (DAs) pose a clinical
challenge. Temozolomide (TMZ) is a recommended treatment option, but its effects are …